By OBBM Network Editorial Staff

Derived from an episode of Get on The Ark.

When chemotherapy’s success rate hovers just above two percent, the question isn’t whether cancer will strike, but how we’ll fight it when it does. Dr. Mike DeFabio, an integrative cancer specialist, argues that the answer lies not in more drugs, but in reviving a century‑old focus on enzymes, nutrition, and the body’s innate healing power.

From Personal Loss to Professional Mission

DeFabio’s commitment to cancer care is rooted in painful family experience. He recounts how his mother and older sister each died at age 67—his mother from cancer and heart disease, his sister from a smoking‑related illness. Those losses, he says, sparked a “calling to help terminally ill people,” a purpose he pursued over three decades of research and clinical practice.

“I asked the Lord that I wanted to have a calling to help terminally ill people,” he says. “God used that injustice to inspire me to do what I do.” This blend of personal grief and spiritual conviction shapes his approach, which he describes as a “science, but the natural side of the science is more therapeutic than conventional.”

The Enzyme Advantage: A Forgotten Frontier

DeFabio highlights the work of early researchers like embryologist John Beard and German biochemist Dr. Johanna Budwig, who explored enzymes and fatty acids as curative agents more than a century ago. Beard’s focus on proteolytic enzymes—those that break down proteins into peptides and amino acids—forms the backbone of DeFabio’s protocol. He explains that pancreatic enzymes, in particular, are “the most therapeutic” because they help restore the body’s immune system by supplying the building blocks of DNA.

“When you break down dietary proteins into peptides and amino acids, that restores the body head to toe,” he asserts. “The bone marrow produces the NK and T cells that attack cancer.” DeFabio’s proprietary “immune kit” claims to combine five key enzymes—protease, lipase, amylase, trypsin, and chymotrypsin—with high activity levels, a mineral complex, and a mushroom extract blend to amplify their effects.

Genetics, Lifestyle, and the Hidden Risks

Contrary to the common belief that DNA mutations are the sole drivers of cancer, DeFabio argues that lifestyle‑induced damage to crucial proteins, such as the P53 tumor‑suppressor gene on chromosome 17, is a major factor. He notes that disturbances in P53, P63, and P73 proteins may account for “50 to 60% of cancers that are life‑threatening.”

He also warns that modern exposures—COVID‑19 vaccines and boosters, certain pharmaceuticals, microplastics, and even contraceptives—are accelerating cancer incidence among younger populations. “Poor lifestyle habits” and “poor immunity” are, in his view, the gateways that allow these genetic vulnerabilities to manifest.

Why Conventional Treatment Falls Short

DeFabio points to stark statistics: late‑stage chemotherapy success rates of 2.3% in Australia and 2.1% in the United States. He contends that the pharmaceutical industry’s profit motive sustains a reliance on chemo and radiation, which he describes as “the biggest business in the drug field.” In contrast, he claims that enzyme‑based therapy can “starve” cancer cells by lowering glucose levels and disrupting the lactic‑acid‑to‑glucose cycle that fuels tumor growth.

“All these things going on. Just keep feeding the cancer 24 hours a day,” he says. “While you’re trying to overcome it, it just keeps feeding it.” His solution is a diet and supplement regimen that reduces blood glucose below 80 mg/dL, thereby limiting the cancer’s primary fuel source.

Faith, Science, and the Path Forward

The conversation repeatedly returns to a biblical framework. DeFabio invokes the story of Noah’s ark as a metaphor for the impending “spiritual storm” that humanity faces, urging listeners to “get on the Ark” by embracing a God‑centered, health‑focused lifestyle. He emphasizes that enzymes are “anointed” by God, positioning natural medicine as a divine provision that modern science is only beginning to rediscover.

“It’s a science, but the natural side of the science is more therapeutic than conventional,” he concludes, urging patients and clinicians alike to reconsider the balance between pharmaceutical interventions and the body’s own healing mechanisms.

In a healthcare landscape dominated by high‑cost treatments and modest success rates, DeFabio’s message challenges the status quo. Whether his enzyme‑centric protocol will gain broader acceptance remains to be seen, but the urgency he conveys—rooted in personal loss, scientific history, and faith—adds a compelling voice to the ongoing debate over cancer care in America.

The full episode of Get on The Ark is available on OBBM Network TV.